KAHD referes to a combination of drugs: Ketoconazole, Hydrocortisone, Dutasteride. An abstract was presented at ASCO 2008. The response rate was equivalent or superior to historical controls, and time to progression was prolonged compared to published durations of 3.5-8.6 months for K/H. The investigators concluded: “These data indicate that addition of D to further suppress intratumor androgen synthesis may result in improved responses, and support a randomized trial to compare KHAD with standard K/H”.
There is an ongoign study: Ketoconazole, Hydrocortisone and Dutasteride in Asymptomatic Hormone Refractory Prostate Cancer (KHAD), NCT00673127. This trial is at Dana Farber but it is no longer accruing. Preliminary results were published in 2008 and 2009 and are referenced.
M. Taplin, Y. Ko, M. M. Regan, T. M. Beer, M. A. Carducci, P. Mathew, G. Bubley, W. K. Oh, P. W. Kantoff, S. P. Balk Phase II trial of ketoconazole, hydrocortisone, and dutasteride (KHAD) for castration resistant prostate cancer (CRPC).J Clin Oncol 26: 2008 (May 20 suppl; abstr 5068)
Yu Chen et al, Antiandrogens and androgen depleting therapies in prostate cancer: novel agents for an established target Lancet Oncol. 2009 October; 10(10): 981–991.